Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607711 | 0.95 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB | |
| SCHEMBL5607707 | 0.93 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB | |
| SCHEMBL5607282 | 0.91 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB | |
| SCHEMBL18635777 | 0.91 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB | |
| SCHEMBL5606800 | 0.90 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB | |
| SCHEMBL5606945 | 0.90 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3C3ALDH1A1HSD17B10 | |
| SCHEMBL5607475 | 0.89 | ALDH1A1 (0.50) | PIK3CDALDH1A1HSD17B10RXFP1HTT | |
| SCHEMBL5606274 | 0.88 | PIK3CD (0.44) | PIK3CDALDH1A1HSD17B10RXFP1 | |
| SCHEMBL5606978 | 0.86 | PIK3CG (0.51) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB | |
| SCHEMBL5607601 | 0.84 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3C3PIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | claimed |
| EP-3102238-A1 | THERAPIES FOR TREATING CANCERS | Gilead Sciences, Inc. (US) | 2016-12-14 | — | — | EP | claimed |
| EP-3074016-A2 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | Gilead Sciences, Inc. (US) | 2016-10-05 | — | — | EP | claimed |
| WO-2015109286-A1 | THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2015081127-A2 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | GILEAD SCIENCES, INC. (US) | 2015-06-04 | — | — | WO | claimed |
| EP-2579878-A1 | METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED PATIENTS | Gilead Calistoga LLC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3860609-A1 | COMBINATION THERAPIES | Secura Bio, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072445-A1 | COMBINATION THERAPIES | VERASTEM, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3474856-A1 | COMBINATION THERAPIES | Infinity Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3350183-A1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Infinity Pharmaceuticals, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2014028665-A1 | COMBINATION THERAPIES FOR TREATING CANCER | GILEAD CALISTOGA LLC (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2579878-A1 | METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED PATIENTS | Gilead Calistoga LLC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2355828-A1 | THERAPIES FOR HEMATOLOGIC MALIGNANCIES | Calistoga Pharmaceuticals Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010057048-A1 | THERAPIES FOR HEMATOLOGIC MALIGNANCIES | CALISTOGA PHARMACEUTICALS INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |